Angiogenesis inhibitors in the treatment of prostate cancer

Bibliography

• Horner MJ RL, Krapcho M, Neyman N, SEER Cancer Statistics Review. 2009 [cited 7/9/2009]. Available from: http://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Roehl KA, Han M, Ramos CG, Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910-4
   PubMedGoogle Scholar
• Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995;32(2):287-92
   PubMedGoogle Scholar
• Immediate versus deferred treatment for advanced prostatic cancer. initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79(2):235-46
   PubMedGoogle Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238-44
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Carducci MA. Novel therapeutic approaches to advanced prostate cancer. Clin Adv Hematol Oncol 2005;3(4):271-82
   PubMedGoogle Scholar
• Rosenberg JE, Weinberg VK, Kelly WK, Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110(3):556-63
   PubMedGoogle Scholar
• Ide A, Baker N, Warren S. Vascularization of the brown-pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 1939;42:891
   Google Scholar
• Folkman J, Cole P, Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966;164(3):491-502
   PubMedGoogle Scholar
• Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007;4(9):536-50
   PubMedGoogle Scholar
• Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175(3):409-16
   PubMedGoogle Scholar
• Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975;82(1):96-100
   PubMedGoogle Scholar
• Ehrmann RL, Knoth M. Choriocarcinoma. transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J Natl Cancer Inst 1968;41(6):1329-41
   PubMedGoogle Scholar
• Greenblatt M, Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 1968;41(1):111-24
   PubMedGoogle Scholar
• Shing Y, Folkman J, Sullivan R, Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984;223(4642):1296-9
   PubMedGoogle Scholar
• Klagsbrun M, Soker S. VEGF/VPF: the angiogenesis factor found? Curr Biol 1993;3(10):699-702
   PubMedGoogle Scholar
• Li Y, Cozzi PJ. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 2009. [Epub ahead of print]
   Google Scholar
• Weidner N, Carroll PR, Flax J, Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143(2):401-9
   PubMedGoogle Scholar
• Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78(7):940-4
   PubMedGoogle Scholar
• Duque JL, Loughlin KR, Adam RM, Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54(3):523-7
   PubMedGoogle Scholar
• George DJ, Halabi S, Shepard TF, Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7(7):1932-6
   PubMedGoogle Scholar
• El-Gohary YM, Silverman JF, Olson PR, Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007;127(4):572-9
   PubMedGoogle Scholar
• Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 2003;116(12):1936-9
   PubMedGoogle Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-74
   PubMed Web of Science ®Google Scholar
• FDA. FDA label information for bevacizumab. 2009 [cited 2009 8/3/2009]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf
   Google Scholar
• Reese DM, Fratesi P, Corry M, Novotny W. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001;3(2):65-70
   Google Scholar
• Picus J, Halabi S, Rini B. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003;22: abstract 1578
   Google Scholar
• Picus J. Docetaxel/bevacizumab (avastin) in prostate cancer [abstract #46]. Cancer Invest 2004;22(Suppl 1):60
   Google Scholar
• Di Lorenzo G, Figg WD, Fossa SD, Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089-94
   PubMedGoogle Scholar
• Phase III randomized study of docetaxel and prednisone with versus without bevacizumab in patients with hormone-refractory metastatic adenocarcinoma of the prostate. [cited 2009 9/9/2009]. Available from: http://www.cancer.gov/clinicaltrials/CALGB-90401
   Google Scholar
• Figg WD, Dahut W, Duray P, A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7(7):1888-93
   PubMedGoogle Scholar
• Ning YM, Arlen PM, Gulley WD, Stein A. A phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-refractory prostate cancer (CRPC). J Clin Oncol 2008;26(Suppl): abstract #5000
   Google Scholar
• Rini BI, Weinberg V, Fong L, Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107(1):67-74
   PubMed Web of Science ®Google Scholar
• Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9(2):263-71
   PubMed Web of Science ®Google Scholar
• Masarelli E, Miller V, Leighl N. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF-Trap) given every 2 weeks in patients (pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol 2007;25(18s): abstract #7627
   Google Scholar
• Tew W, Colombo N, Ray-Coquard A. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007;25(18s): abstract #5508
   Google Scholar
• Ton NC, Parker GJ, Jackson A, Phase I evaluation of CDP791, a PEGylated di-Fab’ conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 2007;13(23):7113-8
   PubMedGoogle Scholar
• Camidge D, Eckhardt S, Diab S, Gore L. A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. J Clin Oncol 2006;24(18s): abstract #3032
   PubMedGoogle Scholar
• Krishnamurthi S, LoRusso P, Goncalves F, Phase I study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies. J Clin Oncol 2008;26(Suppl): abstract #14630
   Google Scholar
• Wedge SR, Kendrew J, Hennequin LF, AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65(10):4389-400
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Stadler WM, Roth B, Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 2007;25(5):445-51
   PubMedGoogle Scholar
• Karakunnel J, Gulley J, Arlen P, Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC). J Clin Oncol 2009;17(15s): abstract #5141
   Google Scholar
• Bradley DP, Tessier JJ, Lacey T, Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate. Magn Reson Imaging 2009;27(3):377-84
   PubMedGoogle Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Dahut WL, Scripture C, Posadas E, A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008;14(1):209-14
   PubMedGoogle Scholar
• Aragon-Ching JB, Jain L, Gulley JL, Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009;103(12):1636-40
   PubMedGoogle Scholar
• Steinbild S, Mross K, Frost A, A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007;97(11):1480-5
   PubMedGoogle Scholar
• Chi KN, Ellard SL, Hotte SJ, A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008;19(4):746-51
   PubMedGoogle Scholar
• Colloca G, Checcaglini F, Venturino A. About sorafenib in castration-resistant prostate cancer. Ann Oncol 2008;19(10):1812-3, author reply 3-4
   PubMedGoogle Scholar
• Scher HI, Halabi S, Tannock I, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59
   PubMedGoogle Scholar
• Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 2008;61(4):535-48
   PubMedGoogle Scholar
• Mardjuadi F, Medioni J, Kerger J, A phase I study of Sorafenib in association with docetaxel-prednisone in chemo-naive metastatic castrate-resistant prostate cancer. J Clin Oncol 2009;27(15s): abstract #5153
   Google Scholar
• Fong TA, Shawver LK, Sun L, SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59(1):99-106
   PubMedGoogle Scholar
• Mendel DB, Laird AD, Smolich BD, Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15(1):29-41
   PubMedGoogle Scholar
• Stadler WM, Cao D, Vogelzang NJ, A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004;10(10):3365-70
   PubMedGoogle Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-96
   PubMed Web of Science ®Google Scholar
• Zurita A, Shore M, Kozloff C, Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) [abstract #230]. ASCO Prostate Cancer Symposium, February 22-24, 2007. Orlando, Florida
   Google Scholar
• Zurita A, Liu G, Hutson T, Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol 2009;27(15s): abstract #5166
   Google Scholar
• Zurita A, Ward J, Araujo C, Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 2008;26(Suppl): abstract #16004
   Google Scholar
• Herbst RS, Heymach JV, O’Reilly MS, Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16(2):239-49
   PubMedGoogle Scholar
• Natale RB, Bodkin D, Govindan R, Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009;27(15):2523-9
   PubMed Web of Science ®Google Scholar
• Teicher BA, Alvarez E, Menon K, Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol 2002;49(1):69-77
   PubMedGoogle Scholar
• Graff JR, McNulty AM, Hanna KR, The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65(16):7462-9
   PubMedGoogle Scholar
• Keyes KA, Mann L, Sherman M, LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53(2):133-40
   PubMedGoogle Scholar
• Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13(1):31-6
   PubMedGoogle Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105(8):1045-7
   PubMedGoogle Scholar
• Browder T, Butterfield CE, Kraling BM, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60(7):1878-86
   PubMed Web of Science ®Google Scholar
• Kakolyris S, Samonis G, Koukourakis M, Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 1998;21(5):505-8
   PubMedGoogle Scholar
• Alvarez A, Mickiewicz E, Brosio C, Reinduction of Response with Weekly Taxol (T) in Advanced Breast Cancer (ABC) 1999 ASCO Annual Meeting. Proc Am Soc Clin Oncol 1999;18:165a, (Abstr 636)
   Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36
   PubMed Web of Science ®Google Scholar
• Hamano Y, Sugimoto H, Soubasakos MA, Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004;64(5):1570-4
   PubMedGoogle Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105(7):2862-8
   PubMedGoogle Scholar
• Glode LM, Barqawi A, Crighton F, Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003;98(8):1643-8
   PubMedGoogle Scholar
• Lord R, Nair S, Schache A, Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007;177(6):2136-40, discussion 40
   PubMedGoogle Scholar
• Fontana A, Galli L, Fioravanti A, Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009;15(15):4954-62
   PubMedGoogle Scholar
• Di Lorenzo G, Autorino R, De Laurentiis M, Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial. Cancer Biol Ther 2007;6(3):313-7
   PubMedGoogle Scholar
• Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52(4):637-40
   PubMedGoogle Scholar
• Chang SS, Reuter VE, Heston WD, Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59(13):3192-8
   PubMed Web of Science ®Google Scholar
• Liu H, Moy P, Kim S, Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57(17):3629-34
   PubMedGoogle Scholar
• Jeske S, Milowsky MI, Smith C, Phase II trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus low-dose interleukin-2 (IL-2) in patients (pts) with recurrent prostate cancer (PC). J Clin Oncol 2007;25(18s): abstract #15558
   Google Scholar
• Bander NH, Milowsky MI, Nanus DM, Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-601
   PubMed Web of Science ®Google Scholar
• Milowsky MI, Nanus DM, Kostakoglu L, Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2522-31
   PubMedGoogle Scholar
• Ng SS, MacPherson GR, Gutschow M, Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res 2004;10(12 Pt 1):4192-7
   PubMedGoogle Scholar
• Li H, Raia V, Bertolini F, Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 2008;101(7):884-8
   PubMedGoogle Scholar
• Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008;27(3):111-35
   PubMedGoogle Scholar
• Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009;10(1):125-33
   PubMedGoogle Scholar
• Kelsey FO. Thalidomide update: regulatory aspects. Teratology 1988;38(3):221-6
   PubMedGoogle Scholar
• Mellin GW, Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962;267:1238-44 concl
   PubMedGoogle Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5
   PubMed Web of Science ®Google Scholar
• Drake MJ, Robson W, Mehta P, An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88(6):822-7
   PubMedGoogle Scholar
• Dixon SC, Kruger EA, Bauer KS, Figg WD. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells. Cancer Chemother Pharmacol 1999;43(Suppl):S78-84
   Google Scholar
• Kurdziel K, Bacharach S, Carrasquillo J, 8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. Clin Positron Imaging 2000;3(4):144
   PubMedGoogle Scholar
• Kurdziel KA, Figg WD, Carrasquillo JA, Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Mol Imaging Biol 2003;5(2):86-93
   PubMedGoogle Scholar
• Figg WD, Arlen P, Gulley J, A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001;28(4 Suppl 15):62-6
   PubMed Web of Science ®Google Scholar
• Dahut WL, Gulley JL, Arlen PM, Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2532-9
   PubMedGoogle Scholar
• Figg W, Retter A, Steinberg S, Dahut W. In reply. J Clin Oncol 2005;23(9):2113-4
   PubMedGoogle Scholar
• Daliani DD, Dieringer C, Papandreou L, Pagliaro L. A tolerance and efficacy study of thalidomide, paclitaxel, and estramustine for patients with chemotherapy refractory androgen independent prostate cancer. Cancer Invest 2004;22(62): abstract #48
   Google Scholar
• Figg WD, Li H, Sissung T, Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007;99(5):1047-55
   PubMedGoogle Scholar
• Figg WD, Hussain MH, Gulley JL, A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol 2009;181(3):1104-13, discussion 13
   PubMedGoogle Scholar
• Amato RJ, Hernandez-McClain J, Henary H. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate. Urol Oncol 2009;27(1):8-13
   PubMedGoogle Scholar
• Tohnya TM, Ng SS, Dahut WL, A phase I study of oral CC-5013 (lenalidomide, revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer 2004;2(4):241-3
   PubMedGoogle Scholar
• Dahut WL, Aragon-Ching JB, Woo S, Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009;49(6):650-60
   PubMedGoogle Scholar
• Sanborn S, Cooney M, Gibbons J. Phase I trial of daily lenalidomide and docetaxel given every three weeks in patients with advanced solid tumors. J Clin Oncol 2007;25: abstract #3570
   Google Scholar
• Sanborn SL, Gibbons J, Krishnamurthi S, Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 2009;27(5):453-60
   Google Scholar
• Moss R, Mohile S, Shelton G, Melia J. A phase I open-label study using lenalidomide and docetaxel in androgen-independent prostate cancer (AIPC). [abstract #89] ASCO Prostate Cancer Symposium, February 22-24, 2007. Orlando, Florida
   Google Scholar
• Pagliaro L, Tannir N, Tu S, Moomey C. A modular phase I study of lenalidomide and paclitaxel in metastatic castrate resistant prostate cancer with prior taxane therapy. J Clin Oncol 2008;26(Suppl): abstract #13545
   PubMedGoogle Scholar
• Garcia JA, Triozzi P, Elson P, Cooney M. Clinical activity of ketoconazole and lenolidomide in castrate progressive prostate carcinoma (CPPCA): preliminary results of a phase II trial. J Clin Oncol 2008;26(Suppl): abstract #5143
   Google Scholar
• Kumar S, Raje N, Hideshima T, Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia 2005;19(7):1253-61
   PubMedGoogle Scholar
• Forsythe JA, Jiang BH, Iyer NV, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16(9):4604-13
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7(5):359-71
   PubMedGoogle Scholar
• Zhong H, De Marzo AM, Laughner E, Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59(22):5830-5
   PubMedGoogle Scholar
• Dikmen ZG, Gellert GC, Dogan P, In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J Cell Biochem 2008;104(3):985-94
   PubMedGoogle Scholar
• Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 2008;34(4):313-27
   PubMedGoogle Scholar
• Sooriakumaran P, Coley HM, Fox SB, A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009;29(5):1483-8
   PubMedGoogle Scholar
• Pruthi RS, Derksen JE, Moore D, Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006;12(7 Pt 1):2172-7
   PubMedGoogle Scholar
• Kearney PM, Baigent C, Godwin J, Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-8
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94
   PubMed Web of Science ®Google Scholar
• Kantoff P, Schuetz T, Blumenstein B, Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009;27(15s): abstract 5013
   Google Scholar